Methotrexate and Cholesterol Transport Regulation: Impact of Treatment Regimen in Diabetes and Metabolic Syndrome Cardiovascular Inflammation

Brief description of study

Cardiovascular Inflammation Reduction Trial (CIRT) sub-study will examine those who have had a heart attack or have documented multi-vessel disease and have either type 2 diabetes or metabolic syndrome (combination of medical disorders). The sub-study is designed to assess the impact of LD MTX (low dose methotrexate) on cholesterol in patients who have suffered a heart attack or who have documented multi-vessel disease. Blood samples from patients who are not taking LD MTX will be compared to samples from patients who are taking LD MTX. This comparsion is necessary to investigate the impact of LD MTX on cholesterol. Research has shown that change in cholesterol transport can affect the risks of life-threatening heart disorders. This sub-study provides an opportunity to evaluate whether the LD MTX is effective and should be continued.


Clinical Study Identifier: s18-01679
Principal Investigator: Joshua R Deleon.
Other Investigators: Juan Gaztanaga, Todd C Kerwin, Kevin P Marzo, Allison B Reiss.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.